Stock comparison
Merck & Co., Inc. is 146.9x more valuable than AbCellera Biologics Inc. by market capitalization ($305.12 B vs $2.08 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 146.9x more valuable than AbCellera Biologics Inc. by market capitalization ($305.12 B vs $2.08 B).
Market value leader
MRK
Merck & Co., Inc. is 146.9x more valuable than AbCellera Biologics Inc. by market capitalization ($305.12 B vs $2.08 B).
Revenue leader
MRK
ABCL: $75.13M vs MRK: $65.01B.
Profit leader
MRK
ABCL: -$146.41M vs MRK: $18.25B.
Margin leader
MRK
ABCL: -194.9% vs MRK: 28.1% net margin.
| Metric | ABCL | MRK |
|---|---|---|
| Market cap | $2.08 B | $305.12 B |
| US-listed rank | #2103 | #44 |
| Revenue (latest FY) | $75.13M | $65.01B |
| Net income (latest FY) | -$146.41M | $18.25B |
| Net margin | -194.9% | 28.1% |
| P/E (trailing FY) | - | 16.7x |
| SEC filings | 297 | 1,000 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 146.9x more valuable than AbCellera Biologics Inc. by market capitalization ($305.12 B vs $2.08 B).
In their latest fiscal years, AbCellera Biologics Inc. reported $75.13M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: AbCellera Biologics Inc. and Merck & Co., Inc., or browse the full rankings.